CEO Mayo Pujols has led Andelyn’s expansion to a full-service gene therapy CMO since joining the company in May 2020. He’s been in the pharma and biotech industry for more than 25 years, including more than five years focused exclusively on cell and gene therapy. Before Andelyn, he led the Global Cell and Gene Technical Development and Manufacturing Division at Novartis, building a global manufacturing network and product pipeline. His experience also includes leadership roles at Celgene, Merck and MedImmune.
.svg)
